Media Thread, page-13180

The great thing is, from quick research on Kincell, manufacturing of CAR-T,s both autologous and allogeneic is in fact their specialty. That isn’t Imugene’s specialty. I think some here think we have handed off a major revenue resource, but in fact all that has happened is another probably much more qualified manufacturer can produce our new product when needed, in a contracted supply agreement, and as LC said, it will allow for IMU to concentrate on their core activities, accessing IMU’s very own AzerCel CAR-T,s as and when required for both trials and hopefully to hospitals for approved treatment further down the track.

I don’t see any negatives here. GLTAH. Onward.